<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436279</url>
  </required_header>
  <id_info>
    <org_study_id>H-31032</org_study_id>
    <secondary_id>AU 6003109</secondary_id>
    <nct_id>NCT01436279</nct_id>
  </id_info>
  <brief_title>Mifepristone Versus Osmotic Dilator Insertion for Cervical Preparation Prior to Surgical Abortion at 15-18 Weeks</brief_title>
  <acronym>SaMi2</acronym>
  <official_title>Mifepristone Versus Osmotic Dilator Insertion for Cervical Preparation Prior to Surgical Abortion at 15-18 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators plan to compare mifepristone and misoprostol use to osmotic
      dilator use for cervical preparation for 15-18 week surgical abortion. Mifepristone would be
      given 24 hours prior to abortion, and misoprostol 400 mcg would be administered buccally 2
      hours prior to abortion. Osmotic dilators are the method currently used in our institution,
      and are placed 24 hours prior to abortion. The primary outcome will be the length of the
      procedure. Secondary outcomes will include amount of dilation achieved, ease of procedure,
      participant's assessment of discomfort before mifepristone or dilators, discomfort during the
      abortion procedure, acceptability to participants, and acceptability to staff.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Procedure</measure>
    <time_frame>Subjects will be followed from the administration of mifepristone/misoprostol or laminaria, until the end of their procedure, a total of two days.</time_frame>
    <description>Interval from speculum insertion to speculum removal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operative Time</measure>
    <time_frame>Subjects will be followed from the administration of mifepristone/misoprostol, or laminaria, until the end of their procedure, a total of two days.</time_frame>
    <description>Interval from initiation of vacuum aspiration to speculum removal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Discomfort Before the Abortion</measure>
    <time_frame>Subjects will be followed from the administration of mifepristone/misoprostol, or laminaria, until the end of their procedure, a total of two days.</time_frame>
    <description>Pain was subjectively described by the subjects as : None, Mild, Moderate, Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Medication (Fentanyl) During the Abortion</measure>
    <time_frame>Subjects will be followed from the administration of mifepristone/misoprostol, or laminaria, until the end of their procedure, a total of two days.</time_frame>
    <description>Amount of pain medication used during the procedure: reported as micrograms of fentanyl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Medication (Midazolam) During the Abortion</measure>
    <time_frame>Subjects will be followed from the administration of mifepristone/misoprostol, or laminaria, until the end of their procedure, a total of two days.</time_frame>
    <description>Amount of pain medication used during the procedure: reported as milligrams of midazolam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cervical Dilation Achieved</measure>
    <time_frame>At time of abortion</time_frame>
    <description>Cervical dilation at start of procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability to Patient</measure>
    <time_frame>After procedure completion</time_frame>
    <description>Patient was asked whether they would choose to be in the same group again if they had a similar procedure again. The number of participants whose response was &quot;yes&quot; is being reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulty of Procedure</measure>
    <time_frame>After completion of procedure</time_frame>
    <description>Outcome measure is the number and percentage of participants where the provider rated the procedure as &quot;difficult or very difficult&quot;. Provider assessment of difficulty of procedure categories were: &quot;very easy&quot;, &quot;easy&quot;, &quot;moderate&quot;, &quot;difficult&quot;, or &quot;very difficult.&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Cervical Preparation</condition>
  <arm_group>
    <arm_group_label>Mifepristone + misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Osmotic dilators</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placed 20-24 hours prior to procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>200 mg po 20-24 hours prior to the procedure</description>
    <arm_group_label>Mifepristone + misoprostol</arm_group_label>
    <other_name>Mifeprex</other_name>
    <other_name>RU-486</other_name>
    <other_name>Mifegyne</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>osmotic dilators</intervention_name>
    <description>osmotic dilators placed in the cervix 20-24 hours prior to the procedure</description>
    <arm_group_label>Osmotic dilators</arm_group_label>
    <other_name>Laminaria</other_name>
    <other_name>Dilapan-S</other_name>
    <other_name>Dilapan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women 18-50 years of age undergoing surgical termination of pregnancy

          -  English or Spanish speaking

          -  Gestational age between 15 and 18 weeks gestation on day of abortion (inclusive), by
             ultrasound dating

          -  Eligible for a dilation and evacuation abortion with local anesthesia and sedation

          -  Ultrasound for dating purposes done within the last two weeks

        Exclusion Criteria:

          -  Intrauterine infection

          -  Fetal demise

          -  Ruptured membranes

          -  Multiple gestation

          -  Uterine anomaly or significant distortion of the uterus with fibroids

          -  BMI greater than 45

          -  Inability to place osmotic dilators

          -  Active substance abuse or intoxication

          -  Adrenal failure, chronic corticosteroid use, anticoagulant usage

          -  Severe cervicitis, until treated and resolved

          -  Prior Cesarean section
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarita Sonalkar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2011</study_first_submitted>
  <study_first_submitted_qc>September 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <results_first_submitted>April 11, 2017</results_first_submitted>
  <results_first_submitted_qc>May 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mifepristone + Misoprostol</title>
          <description>Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure
Mifepristone: 200 mg po 20-24 hours prior to the procedure</description>
        </group>
        <group group_id="P2">
          <title>Osmotic Dilators</title>
          <description>Placed 20-24 hours prior to procedure
osmotic dilators: osmotic dilators placed in the cervix 20-24 hours prior to the procedure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mifepristone + Misoprostol</title>
          <description>Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure</description>
        </group>
        <group group_id="B2">
          <title>Osmotic Dilators</title>
          <description>Placed 20-24 hours prior to procedure</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Length of Procedure</title>
        <description>Interval from speculum insertion to speculum removal</description>
        <time_frame>Subjects will be followed from the administration of mifepristone/misoprostol or laminaria, until the end of their procedure, a total of two days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mifepristone + Misoprostol</title>
            <description>Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators</title>
            <description>Placed 20-24 hours prior to procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Procedure</title>
          <description>Interval from speculum insertion to speculum removal</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="12" upper_limit="17"/>
                    <measurement group_id="O2" value="13.5" lower_limit="11" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Operative Time</title>
        <description>Interval from initiation of vacuum aspiration to speculum removal</description>
        <time_frame>Subjects will be followed from the administration of mifepristone/misoprostol, or laminaria, until the end of their procedure, a total of two days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mifepristone + Misoprostol</title>
            <description>Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure
Mifepristone: 200 mg po 20-24 hours prior to the procedure</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators</title>
            <description>Placed 20-24 hours prior to procedure
osmotic dilators: osmotic dilators placed in the cervix 20-24 hours prior to the procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Operative Time</title>
          <description>Interval from initiation of vacuum aspiration to speculum removal</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="12"/>
                    <measurement group_id="O2" value="8.5" lower_limit="7" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Discomfort Before the Abortion</title>
        <description>Pain was subjectively described by the subjects as : None, Mild, Moderate, Severe</description>
        <time_frame>Subjects will be followed from the administration of mifepristone/misoprostol, or laminaria, until the end of their procedure, a total of two days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mifepristone + Misoprostol</title>
            <description>Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure
Mifepristone: 200 mg po 20-24 hours prior to the procedure</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators</title>
            <description>Placed 20-24 hours prior to procedure
osmotic dilators: osmotic dilators placed in the cervix 20-24 hours prior to the procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Discomfort Before the Abortion</title>
          <description>Pain was subjectively described by the subjects as : None, Mild, Moderate, Severe</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Medication (Fentanyl) During the Abortion</title>
        <description>Amount of pain medication used during the procedure: reported as micrograms of fentanyl</description>
        <time_frame>Subjects will be followed from the administration of mifepristone/misoprostol, or laminaria, until the end of their procedure, a total of two days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mifepristone + Misoprostol</title>
            <description>Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators</title>
            <description>Placed 20-24 hours prior to procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Medication (Fentanyl) During the Abortion</title>
          <description>Amount of pain medication used during the procedure: reported as micrograms of fentanyl</description>
          <units>mcg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1.34"/>
                    <measurement group_id="O2" value="2.9" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Medication (Midazolam) During the Abortion</title>
        <description>Amount of pain medication used during the procedure: reported as milligrams of midazolam</description>
        <time_frame>Subjects will be followed from the administration of mifepristone/misoprostol, or laminaria, until the end of their procedure, a total of two days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mifepristone + Misoprostol</title>
            <description>Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators</title>
            <description>Placed 20-24 hours prior to procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Medication (Midazolam) During the Abortion</title>
          <description>Amount of pain medication used during the procedure: reported as milligrams of midazolam</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" spread="31"/>
                    <measurement group_id="O2" value="105" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cervical Dilation Achieved</title>
        <description>Cervical dilation at start of procedure</description>
        <time_frame>At time of abortion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mifepristone + Misoprostol</title>
            <description>Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure
Mifepristone: 200 mg po 20-24 hours prior to the procedure</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators</title>
            <description>Placed 20-24 hours prior to procedure
osmotic dilators: osmotic dilators placed in the cervix 20-24 hours prior to the procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Cervical Dilation Achieved</title>
          <description>Cervical dilation at start of procedure</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="11"/>
                    <measurement group_id="O2" value="56" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acceptability to Patient</title>
        <description>Patient was asked whether they would choose to be in the same group again if they had a similar procedure again. The number of participants whose response was &quot;yes&quot; is being reported.</description>
        <time_frame>After procedure completion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mifepristone + Misoprostol</title>
            <description>Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure
Mifepristone: 200 mg po 20-24 hours prior to the procedure</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators</title>
            <description>Placed 20-24 hours prior to procedure
osmotic dilators: osmotic dilators placed in the cervix 20-24 hours prior to the procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability to Patient</title>
          <description>Patient was asked whether they would choose to be in the same group again if they had a similar procedure again. The number of participants whose response was &quot;yes&quot; is being reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difficulty of Procedure</title>
        <description>Outcome measure is the number and percentage of participants where the provider rated the procedure as &quot;difficult or very difficult&quot;. Provider assessment of difficulty of procedure categories were: &quot;very easy&quot;, &quot;easy&quot;, &quot;moderate&quot;, &quot;difficult&quot;, or &quot;very difficult.&quot;</description>
        <time_frame>After completion of procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mifepristone + Misoprostol</title>
            <description>Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure
Mifepristone: 200 mg po 20-24 hours prior to the procedure</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators</title>
            <description>Placed 20-24 hours prior to procedure
osmotic dilators: osmotic dilators placed in the cervix 20-24 hours prior to the procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Difficulty of Procedure</title>
          <description>Outcome measure is the number and percentage of participants where the provider rated the procedure as &quot;difficult or very difficult&quot;. Provider assessment of difficulty of procedure categories were: &quot;very easy&quot;, &quot;easy&quot;, &quot;moderate&quot;, &quot;difficult&quot;, or &quot;very difficult.&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mifepristone + Misoprostol</title>
          <description>Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure
Mifepristone: 200 mg po 20-24 hours prior to the procedure</description>
        </group>
        <group group_id="E2">
          <title>Osmotic Dilators</title>
          <description>Placed 20-24 hours prior to procedure
osmotic dilators: osmotic dilators placed in the cervix 20-24 hours prior to the procedure</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Olivera Vragovic</name_or_title>
      <organization>Boston Medical Center</organization>
      <phone>617 414 7304</phone>
      <email>Olivera.Vragovic@bmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

